Ibrutinib and Rituximab in Waldenström's Macroglobulinemia

Francesco Cavazzini^{1

2}, Gian Matteo Rigolin¹, Antonio Cuneo¹

Affiliations

Comment

Francesco Cavazzini et al. N Engl J Med. 2018.

. 2018 Nov 15;379(20):1974-5.

doi: 10.1056/NEJMc1809505.

Francesco Cavazzini^{1

2}, Gian Matteo Rigolin¹, Antonio Cuneo¹

No abstract available

Comment in

Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.
Dimopoulos MA, Salman Z, Buske C. Dimopoulos MA, et al. N Engl J Med. 2018 Nov 15;379(20):1975-1976. doi: 10.1056/NEJMc1809505. N Engl J Med. 2018. PMID: 30428288 No abstract available.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Dimopoulos MA, et al. N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1. N Engl J Med. 2018. PMID: 29856685 Clinical Trial.